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The pituitary gland and infundibulum can be involved in a variety of medical conditions, including inﬁltrative diseases, fungal
infections, tuberculosis, and primary and metastatic tumors. Metastases to the pituitary gland are absolutely rare, and they are
generally secondary to pulmonary carcinoma in men and breast carcinoma in women. Pituitary metastases more commonly aﬀect
the posterior lobe and the infundibulum than the anterior lobe. The posterior lobe involvement may explain why patients with
pituitary metastases frequently present with diabetes insipidus. We are presenting a case report of a 78-year-old male patient
who had metastatic prostate with sudden onset of polyuria and persistent thirst. He had no electrolyte imbalance except mild
hypernatremia. The MRI scan of the brain yielded a suspicious area in pituitary gland. A pituitary stalk metastasis was found
on magnetic resonance imaging (MRI) of pituitary. Water deprivation test was compatible with DI. A clinical response to nasal
vasopressin was achieved and laboratory results revealed central diabetes insipidus. As a result, the intrasellar and suprasellar
masses decreased in size, and urinary output accordingly decreased.
1.Introduction
Diabetes insipidus is a disorder of a large volume of urine
(diabetes) that is hypotonic, dilute, and tasteless (insipid).
This is opposed to the hypertonic and sweet urine of diabetes
mellitus(honey).Fourpathophysiologicmechanismsrelated
to vasopressin produce large volumes of dilute urine and
polydipsia:
(1) hypothalamic (central or neurohypophyseal) dia-
betes insipidus with inability to secrete and usually to
synthesize vasopressin in the neurohypophyseal sys-
tem,
(2) nephrogenic diabetes insipidus wherein there is an
inappropriate renal response to vasopressin,
(3) transient diabetes insipidus of pregnancy produced
by the accelerated metabolism of vasopressin,
(4) primary polydipsia wherein the initial pathophysiol-
ogy is the ingestion of ﬂuid rather than the excretion
of ﬂuid.
Metastaticdiseaseinvolvingthepituitaryisusuallyfound
in association with widespread metastatic disease and may
only be reported at autopsy, being asymptomatic during life.
Metastasesaretwiceaslikelytoinvolvetheposteriorpituitary
as the anterior pituitary, which is thought to be due to a
more direct arterial blood supply to the posterior pituitary.
Most primary tumors in the hypothalamic-pituitary area
that cause diabetes insipidus are relatively slow growing,
and any tumor in this area that shows rapid growth in a
short period of time should be considered to be a possible
metastatic tumor.
Diabetes insipidus is reported with lymphomas in the
hypothalamic/pituitary area. There may be some increased2 Case Reports in Medicine
incidence of lymphoma presenting with diabetes insipidus
due to the increased incidence of lymphoproliferative disease
with human immunodeﬁciency virus (HIV) and hepatitis C
infection.Diabetesinsipidusisalsoassociatedwithleukemia.
The mechanism is thought to be inﬁltration of the hypotha-
lamus, thrombosis, or infection. Diabetes insipidus is dis-
tinctly more common in nonlymphocytic leukemia. MRI
studies in leukemia may show inﬁltration or an infundibular
mass, but often results are normal even when leukemic cells
are found in the cerebrospinal ﬂuid (CSF).
Primary or secondary (most often due to lung cancer,
leukemia, or lymphoma) tumors in the brain can involve the
hypothalamic-pituitary region and lead to central diabetes
insipidus (CDI). In some patients with metastatic disease,
polyuria is the presenting symptom. We found two case
reports about pituitary gland metastasis from carcinoma of
the prostate [1, 2]. But two case reports presented pituitary
mass aﬀect no central diabetes insipidus. We reported the
ﬁrst case about apatient who has central diabetes insipidus
with metastatic prostate cancer due to only posterior pitu-
itary metastasis.
2.CaseReport
Aman76-year-oldwasadmittedtoourhospitalwithurinary
urgency. On admission, the other systems examinations
were normal. But on digital rectal examination, there was
asymmetricareasofinduration.FirstPSA:18.2ng/mL.Tran-
srectal biopsy of the prostate was performed with transrectal
ultrasound (TRUS)-guided. Biopsy has proven Geason grade
4+4= score 8 adenocarcinoma. He was treated with open
prostatectomy, and TNM stage is T3 N0 M0. Hormonal
treatment with leuprolide was started. He has used the
drug presently. One year later, he complained back pain.
He did not come back to my hospital, but six months
later, he complained about polyuria, polydipsia, and loss of
weight without blindness, ophthalmoplegia in his eyes, and
impairment of memory and mental status. Other problems
were constipation, loss of appetite, and drowsiness. He did
not have a headache. Physical examination showed signs of
dehydration. PSA level was 120ng/mL (normal < 4ng/dL).
Further laboratory results are shown in Table 1. A 99mTc-
diphosphate bone scan revealed metastases in the spine, ribs,
and femurs (Figure 1). MRI-scan with gadolinium contrast
suggested a lesion (5 × 8mm) in the posterior part of
the pituitary, relatively isodense to the brain in T1- and
T2-weighed images, and loss of the normal high signal
from the posterior lobe of the pituitary gland (Figures 2
and 3). We think central diabetes insipidus secondary
to metastatic prostate carcinoma. We began desmopressin
therapy (10microg of the nasal spray) for central diabetes
insipidus. We suggested local external beam radiation ther-
apy for lumbar and thoracic vertebral bones and pituitary
with chemotherapy to the patient, but he did not accept. He
improved symptoms (polyuria, polydipsia); Sodium (from
151 to 137), and urine output decreased (from 9.2 to 2.1)
two weeks later in Table 1.
Table 1: Baseline and after treatment endocrinological and bio-
chemical evaluation.
First After
treatment Normal range
Serum
TSH 0.60 0.85 0.4–
5.5microIU/mL
Free T4 1.28 1.31 0.74–1.52ng/dL
Free T3 2.4 2.6 2.3–4.2pg/mL
FSH 5.3 4.1 1.9–18.9IU/L
LH 0.7 0.8 1.7–9.6IU/L
Total testosterone 18 14 370–1000ng/dL
Prolactin 5.8 12.1 2.7–18.3ng/mL
IGF-1 98 100 84–238ng/mL
ACTH 14.2 15.1 7–46pg/mL
Basal cortisol 18.3 18.4 4.6–22.80μg/dL
Sodium 151 137 132–146mEq/L
Calcium 9.2 9.1 8.6–10.2mg/dL
Creatinine 0.79 0.78 0.7–1.3mg/dL
Potassium 5 4.6 3.5–5.5mEq/L
Urea 26 28 19–48mg/dL
Albumin 4.1 3.9 3.2–4.8mg/dL
Osmolality 315 292 285–300
Urine
Volume (1 day) 9.2 2.1 lt
Speciﬁc gravity 1.001 1.018 1.010–1.020
Osmolality (mosm/kg) 78 450 300–
1090mosm/kg
3. Discussion
Diabetes insipidus is a syndrome characterised by hypotonic
polyuria and polydipsia, either as a result of inadequate
antidiuretic hormone (ADH) secretion central diabetes
insipidus(CDI),inadequaterenalresponsetoADH(nephro-
genic diabetes insipidus), or primary polydipsia [3, 4].
Causes of CDI are congenital or acquired lesions that
disrupt the neurons that originate in the supraoptic and
paraventricular nuclei of the hypothalamus axis. These
lesions are malformations, damage resulting from surgery
or trauma, tumours, haemorrhage, thrombosis, infarction
or granulomatous disease. Some 30 to 50% of cases are
idiopathic [5, 6]. Primary tumours are craniopharyngioma,
meningioma, or germinoma, but secondary tumours can
also occur. Metastases in the posterior pituitary lobe are
more common than in the anterior lobe, possibly caused
by the direct blood supply of the posterior lobe from the
systemic circulation. In 1857, L. Benjamin ﬁrst described a
case of metastasis to the pituitary (MP) gland in an autopsy
of a patient with disseminated melanoma [5]. Since then,
a number of surgical and autopsy series and sporadic case
reportshavedescribedmetastatictumorstothepituitary.MP
is an infrequent clinical problem reported in 0.14–28.1% of
all brain metastases in autopsy series [5–7].Case Reports in Medicine 3
Figure 1: Bone scan: all bone metastases—rib, femur, pelvis, spine
bone metastases.
Figure 2: T2-weighted MRI demonstrated that 5 × 8mmmassthe
has irregular borderline.
Breast cancer is the most common tumor to metastasize
to the pituitary gland (varying from 5.3 to 28%) [8, 9]; its
frequency is followed by that of lung cancer. Prostate [1, 2],
r e n a lc e l l[ 10, 11], gastrointestinal cancers [12], lymphoma
[13], leukemia, thyroid carcinoma [14], and plasmacytoma
[15] have also been reported. We hypothesized that the pos-
terior pituitary, by receiving a direct arterial blood supply, is
more likely to develop metastases than the adenohypophysis,
which receives its blood supply from the hypophyseal portal
system. Therefore, hematogenous spreads of malignant cells
disseminate easier to posterior part of hypophysis than to
the anterior lobe, which is supplied by hypophyseal portal
system.
MRI is the most useful imaging modality for pituitary
pathologies. Hypophysis, stalk, cavernous sinuses, sphenoid
sinus, and optic chiasma are well evaluated on coronal and
sagittal T1-weighted MRI both before and after Gadolinium
injection [16]. Lesions on MRI may be seen as cystic,
nodular, or stalk thickening. On MRI, the posterior pituitary
Figure 3: MRI showed that 5 × 8mm mass the has irregular bor-
derline (arrow).
is identiﬁed by hyperintensity, probably caused by phos-
pholipids or secretory granules in pituicytes [17]. A lack of
this hyperintensity on sagittal T1-weighted images, as was
observed in our patient, is the hallmark of hypothalamic
posteriorpituitarydisordersandmayrepresentanearlystage
of tumour inﬁltration [4, 18]. A thickened pituitary stalk
could be another indicative ﬁnding [19]. We found two case
reports about pituitary gland metastasis from carcinoma of
the prostate [1, 2]. But two case reports presented pituitary
mass aﬀect no central diabetes insipidus. We reported a ﬁrst
case of a patient who has central diabetes insipidus with
metastatic prostate cancer due to only posterior pituitary
metastasis.
Management of these patients may also be very diﬃcult
because the prognosis depends on the course of the primary
neoplasm. Treatment, being basically palliative, depends on
the symptoms and the extent of the systemic disease [20].
In known cancer patients, a full investigation for additional
metastases is mandatory. Multiple treatment modalities exist
for pituitary metastases (MP) including resection, radiation
therapy, and chemotherapy. The surgical indications are a
symptomatic mass lesion [20]. Nonetheless, surgery is more
diﬃcult compared to primary pituitary adenomas because
blood loss is greater, and the lesion could be attached
to the surrounding structures or show considerable inva-
siveness [20]. Reports of surgery of MPs indicate that the
lesions tend to be ﬁrm, diﬀuse, invasive, vascular, and
hemorrhagic; therefore, their total resection is unlikely. In
this setting, local radiation and/or chemotherapy are recom-
mended as the initial course of treatment, especially in
patients with widespread metastases, in combination with
pituitary hormone substitution therapy. Surgical exploration
and decompression, alone or combined with radiation, is
essential if clariﬁcation of diagnosis is likely to aﬀect therapy
or if suprasellar extension causes progressive deterioration
in vision or pain. Surgery and radiation are well toler-
ated in noncompromised patients, being associated with
low morbidity and minimal complications. Radiosurgery
(gamma knife radiosurgery) may be considered less invasive
than conventional radiation therapy from the standpoint4 Case Reports in Medicine
of radiation eﬀects on the surrounding structures. One
patient has been treated by gamma knife radiosurgery
with metastatic pituitary carcinoid tumor resulting in rapid
decrease of tumour size [21].
4. Conclusion
Inconclusion,incancerpatientswhohavesymptomssuchas
nausea,vomiting,polyuria,andpolydipsiawhiletheyarenot
onchemotherapyshouldbeevaluatedfornot onlymetabolic
complications like hypercalcemia and hypokalemia but also
posterior pituitary or stalk metastasis. MRI could be the
choice of imaging for pituitary metastasis. We could think
that sudden onset of diabetes insipidus pituitary metastases
should be taken in to account in diﬀerential diagnosis.
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